Among them, more datasets support the lower expression of CD58 in leukemia, lung cancer, and sarcoma, while its expression was significantly increased in bladder cancer, brain and CNS cancer, and pancreatic cancer, compared with corresponding normal tissues (Fig. 1b). This evidence concerns the gene CD58 and central nervous system cancer.